

Table 10.1
Kaposi Sarcoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2017

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2013	2014- 2015	2016- 2017
SEER 9 ^b	134	80	324	888	1,571	2,132	2,231	2,057	1,803	842	394	403	339	372	341	346	349	323	304	273
SEER 9 except SF-Oakland	102	45	86	261	428	776	842	976	877	465	246	266	226	246	244	252	251	248	225	199
San Francisco- Oakland SMSA ^c	32	35	238	627	1,143	1,356	1,389	1,081	926	377	148	137	113	126	97	94	98	75	79	74
San Francisco City/County	15	21	198	539	951	1,077	1,088	792	689	254	86	82	72	82	62	62	66	40	50	43

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2017

All Races, Males, All Ages

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2013	2014- 2015	2016- 2017
SEER 9 ^b	0.4	0.6	1.7	4.2	7.1	9.2	9.3	8.2	7.0	3.2	1.5	1.5	1.3	1.4	1.3	1.3	1.2	1.1	1.0	0.9
SEER 9 except SF-Oakland	0.4	0.4	0.6	1.6	2.3	4.0	4.2	4.6	4.0	2.1	1.1	1.2	1.0	1.1	1.1	1.1	1.1	1.0	0.9	0.8
San Francisco- Oakland SMSA ^c	0.7	1.3	6.9	17.2	30.0	34.1	34.0	25.6	22.0	9.0	3.5	3.1	2.7	2.9	2.3	2.1	2.2	1.6	1.6	1.5
San Francisco City/County	1.1	3.1	24.8	65.2	111.0	125.0	125.8	89.1	77.4	28.3	9.4	8.9	8.0	9.1	6.8	6.7	7.0	4.0	5.0	4.2

^a Rates are per 100,000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi Sarcoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 10.2

Kaposi Sarcoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2017

All Races, Males, Ages 20-54

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2013	2014- 2015	2016- 2017
SEER 9 ^b	13	27	252	805	1,478	1,995	2,102	1,923	1,677	756	321	349	265	310	274	254	250	246	217	189
SEER 9 except SF-Oakland	11	-	36	207	379	695	773	910	812	411	199	228	187	203	201	186	177	196	170	148
San Francisco- Oakland SMSA ^c	-	21	216	598	1,099	1,300	1,329	1,013	865	345	122	121	78	107	73	68	73	50	47	41
San Francisco City/County	-	18	190	519	921	1,041	1,050	748	647	237	76	75	54	72	53	50	54	29	33	26

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2017

All Races, Males, Ages 20-54

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2013	2014- 2015	2016- 2017
SEER 9 ^b	0.1	0.3	2.4	7.4	13.1	16.9	17.1	14.9	12.7	5.6	2.3	2.5	1.9	2.3	2.0	1.9	1.8	1.7	1.5	1.3
SEER 9 except SF-Oakland	0.1	-	0.4	2.2	3.9	6.9	7.4	8.4	7.2	3.6	1.7	2.0	1.6	1.8	1.8	1.6	1.5	1.7	1.4	1.2
San Francisco- Oakland SMSA ^c	-	1.3	11.9	32.3	57.2	64.6	63.9	46.9	40.1	15.9	5.4	5.3	3.4	4.9	3.3	3.1	3.3	2.2	2.0	1.8
San Francisco City/County	-	5.3	47.3	125.1	213.7	239.9	240.6	165.5	142.3	51.8	16.0	15.9	11.4	15.8	11.5	10.7	11.5	5.8	6.8	5.3

^a Rates are per 100,000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi Sarcoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 10.3

Kaposi Sarcoma

Number of Cases

By SEER Location and Year of Diagnosis, 1975-2017

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2013	2014- 2015	2016- 2017
SEER 9 ^b	121	53	71	82	92	135	129	133	126	86	73	53	74	61	67	91	95	77	87	83
SEER 9 except SF-Oakland	91	39	49	54	49	81	69	65	65	54	47	37	39	42	43	65	71	52	55	50
San Francisco- Oakland SMSA ^c	30	14	22	28	43	54	60	68	61	32	26	16	35	19	24	26	24	25	32	33
San Francisco City/County	14	-	-	20	30	35	38	44	42	17	10	-	18	10	-	12	11	11	17	17

Age-Adjusted Cancer Incidence Rates^a

By SEER Location and Year of Diagnosis, 1975-2017

All Races, Males, Ages 55+

Year of Diagnosis

SEER Location	1975- 1979	1980- 1981	1982- 1983	1984- 1985	1986- 1987	1988- 1989	1990- 1991	1992- 1993	1994- 1995	1996- 1997	1998- 1999	2000- 2001	2002- 2003	2004- 2005	2006- 2007	2008- 2009	2010- 2011	2012- 2013	2014- 2015	2016- 2017
SEER 9 ^b	1.9	1.9	2.4	2.5	2.5	3.6	3.6	3.3	3.0	2.1	1.7	1.3	1.5	1.2	1.3	1.6	1.5	1.2	1.2	1.1
SEER 9 except SF-Oakland	1.7	1.7	2.0	2.0	1.8	2.7	2.4	2.0	1.9	1.7	1.3	1.1	1.0	1.0	1.0	1.4	1.4	1.0	0.9	0.8
San Francisco- Oakland SMSA ^c	2.9	3.1	4.6	4.7	6.4	8.1	9.6	10.1	9.0	4.8	3.7	2.3	4.5	2.3	2.8	2.9	2.4	2.3	2.8	2.7
San Francisco City/County	4.7	-	-	12.9	19.8	23.5	26.4	30.4	29.8	11.5	6.7	-	10.8	5.7	-	6.3	5.2	5.4	7.5	7.2

^a Rates are per 100,000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).^b The SEER 9 areas are San Francisco-Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.^c The San Francisco-Oakland SMSA represents 15% of all persons in the SEER areas. For this age group, all SEER areas may not be generalizable to the United States for Kaposi Sarcoma.

- Statistic not shown. Rate based on less than 4 cases for the time interval.

Table 10.4
Kaposi Sarcoma

Age-adjusted SEER Incidence^a Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975-2017	1.53	2.99	0.12	1.57	3.05	0.10	2.08	4.22	0.25
1975-1979	0.24	0.44	0.11	0.23	0.44	0.11	-	-	-
1980	0.28	0.56	-	0.31	0.62	-	-	-	-
1981	0.32	0.54	-	0.34	0.61	-	-	-	-
1982	0.65	1.20	0.18	0.70	1.30	0.18	-	-	-
1983	1.07	2.18	-	1.18	2.39	-	-	-	-
1984	1.81	3.59	-	2.00	3.93	-	1.27	2.89	-
1985	2.46	4.86	0.16	2.79	5.47	0.18	1.09	2.24	-
1986	3.27	6.52	-	3.70	7.32	-	1.65	3.59	-
1987	3.80	7.60	-	4.25	8.44	-	2.09	4.29	-
1988	4.43	8.87	0.15	4.82	9.56	0.15	3.40	7.28	-
1989	4.77	9.54	0.14	5.13	10.18	-	4.64	9.84	-
1990	4.61	9.22	0.18	5.04	9.99	0.16	3.65	7.54	-
1991	4.70	9.40	0.19	5.04	10.00	0.18	4.59	9.53	-
1992	4.38	8.68	0.18	4.60	9.02	0.18	5.08	10.72	-
1993	3.86	7.64	0.17	4.05	7.96	0.15	4.28	8.60	-
1994	3.79	7.47	0.17	3.87	7.57	0.14	4.25	8.63	-
1995	3.30	6.47	0.20	3.26	6.33	0.17	5.03	10.46	-
1996	2.24	4.41	0.16	2.01	4.00	-	4.67	9.21	-
1997	1.08	2.09	0.13	0.92	1.79	-	2.77	5.52	-
1998	0.81	1.58	-	0.70	1.34	-	1.79	3.78	-
1999	0.79	1.48	0.13	0.66	1.26	-	1.94	3.72	-
2000	0.80	1.55	-	0.67	1.30	-	1.99	4.00	-
2001	0.83	1.52	0.17	0.68	1.21	0.15	2.02	4.03	-
2002	0.69	1.30	0.12	0.59	1.10	-	1.51	3.05	-
2003	0.67	1.29	-	0.60	1.13	-	1.52	3.21	-
2004	0.70	1.35	-	0.60	1.16	-	1.69	3.41	-
2005	0.78	1.48	0.13	0.61	1.16	-	2.08	4.07	-
2006	0.62	1.22	-	0.53	1.02	-	1.44	2.93	-
2007	0.70	1.33	-	0.58	1.08	-	1.73	3.57	-
2008	0.68	1.34	-	0.57	1.12	-	1.66	3.22	-
2009	0.64	1.21	0.11	0.54	1.03	-	1.48	2.90	-
2010	0.65	1.22	0.09	0.45	0.85	-	1.91	3.88	-
2011	0.65	1.27	-	0.48	0.94	-	1.96	4.08	-
2012	0.67	1.28	0.09	0.50	0.94	-	1.85	3.71	-
2013	0.53	0.98	-	0.38	0.72	-	1.53	2.91	-
2014	0.58	1.08	0.10	0.40	0.74	-	1.69	3.19	-
2015	0.52	0.95	0.11	0.37	0.65	-	1.49	2.84	-
2016	0.52	0.96	0.10	0.36	0.66	-	1.43	2.81	-
2017	0.45	0.83	-	0.30	0.56	-	1.41	2.78	-

^a Individual rates for diagnosis years 1975-1979 available in web browser version of [Cancer Statistics Review](#).
SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 10.5
Kaposi SarcomaSEER Incidence^a Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence</u>									
<u>Age at Diagnosis</u>									
Age-Adjusted Rates, 2013-2017									
All ages	0.5	0.9	0.1	0.4	0.7	0.1	1.0	2.0	0.2
Under 65	0.4	0.8	0.0	0.3	0.6	0.0	1.0	2.0	0.2
65 and over	1.0	1.7	0.5	0.9	1.6	0.4	0.9	1.8	0.4
All ages (WHO world std) ^b	0.4	0.8	0.1	0.3	0.6	0.0	1.0	1.8	0.2
Age-Specific Rates, 2013-2017									
<1	-	-	-	-	-	-	-	-	-
1-4	-	-	-	-	-	-	-	-	-
5-9	-	-	-	-	-	-	-	-	-
10-14	-	-	-	-	-	-	-	-	-
15-19	-	-	-	-	-	-	-	-	-
20-24	0.2	0.4	-	0.1	0.2	-	0.8	1.5	-
25-29	0.6	1.1	-	0.3	0.6	-	2.0	4.0	-
30-34	0.8	1.5	0.1	0.4	0.9	-	2.7	5.1	-
35-39	0.6	1.2	-	0.4	0.8	-	1.9	3.7	-
40-44	0.7	1.3	0.1	0.5	1.0	-	1.5	2.8	-
45-49	0.8	1.6	-	0.7	1.3	-	1.3	2.6	-
50-54	0.7	1.3	0.1	0.6	1.1	-	1.2	2.3	-
55-59	0.6	1.1	-	0.6	1.1	-	0.9	1.7	-
60-64	0.5	1.0	-	0.5	0.9	-	0.8	1.6	-
65-69	0.5	1.0	0.1	0.5	0.9	-	0.7	1.5	-
70-74	0.7	1.2	0.2	0.6	1.0	0.2	0.9	-	-
75-79	1.1	1.8	0.6	1.1	1.8	0.5	-	-	-
80-84	1.4	2.4	0.7	1.3	2.3	0.6	-	-	-
85+	1.8	3.1	1.2	1.8	3.1	1.2	-	-	-

^a SEER 21 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

^b Rates are per 100,000 and are age-adjusted to the world (WHO 2000-2025) standard million.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 10.6
Kaposi Sarcoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	80.7 ^f	80.1 ^f	-	79.9 ^f	79.0 ^f	-	-	-	-
1978-1980 ^b	78.3 ^f	79.4 ^f	73.1 ^g	78.0 ^f	78.4 ^f	72.5 ^g	-	-	-
1981-1983 ^b	35.7	33.4	64.3 ^g	34.0	31.6	64.2 ^g	-	-	-
1984-1986 ^b	13.0	11.7	70.5 ^g	12.8	11.4	70.2 ^g	16.8	15.7	-
1987-1989 ^b	9.9	9.3	68.5 ^g	9.4	8.8	72.4 ^g	12.4	11.3	-
1990-1992 ^b	9.3	8.6	53.9 ^f	8.9	8.2	55.4 ^f	11.8	10.8	-
1993-1995 ^b	21.8	21.1	53.8 ^f	22.1	21.3	62.1 ^g	17.5	16.7	-
1996-1998 ^b	52.4	51.6	71.4 ^g	57.1	55.9	85.9 ^f	40.2	39.7	-
1999-2001 ^b	58.3	57.9	60.0 ^f	64.8	63.3	78.4 ^g	44.1	45.6	-
2002-2004 ^b	64.7	63.8	71.1 ^g	75.2	74.1	76.9 ^g	42.0	42.2	-
2005-2009 ^b	74.3	74.5	70.7 ^f	81.4	81.5	76.0 ^f	59.8	60.2	-
2010-2016 ^b	76.3 ^e	76.2	75.3 ^f	82.0	81.1	83.7 ^f	66.0	67.6	37.9 ^g
5-Year Period Survival (Percent) ^{cd}									
2016	74.6	73.8	80.7	77.6	75.5	90.7	63.5	65.3	33.4
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	68.4	69.1	46.2 ^f	70.3	70.3	-	64.4	65.5	39.1 ^g
Ages 45-54	73.1	73.6	-	75.9	75.7	-	61.9	64.1	-
Ages 55-64	81.4	82.1	-	83.0	82.4	-	75.3 ^f	82.6 ^f	-
Ages 65-74	84.7	83.4	85.4 ^f	82.7	80.3	87.9 ^f	-	-	-
Ages 75+	85.2	76.9 ^f	86.0 ^f	85.9 ^f	77.1 ^f	86.9 ^f	-	-	-
Ages <65	71.6	72.2	55.0 ^f	74.6	74.3	82.2 ^f	64.6	66.3	34.0 ^f
Ages 65+	85.7	81.2	86.6	85.2	79.6	87.9 ^f	65.7 ^g	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.
^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.
^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
Based on follow-up of patients into 2017.
^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).
^e The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).
^f The standard error is between 5 and 10 percentage points.
^g The standard error is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 10.7
Kaposi SarcomaSEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																									
	1975-1979	1980-1984	1985-1989	1990-1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
1-year	94.4	65.4	59.0	59.0	61.8	69.0	72.8	73.8	76.8	74.1	80.5	78.1	75.3	82.6	82.1	81.7	82.8	80.0	82.3	83.5	85.2	80.6	86.6	87.3	83.7	82.2
2-year	89.6	44.5	32.8	29.4	46.8	60.4	65.1	65.5	65.1	66.3	73.4	71.1	72.5	73.5	78.8	79.0	80.4	76.1	79.5	77.7	81.5	80.5	83.9	80.1	79.2	
3-year	88.7	36.1	19.8	18.3	42.9	54.1	62.1	61.1	61.5	60.1	67.6	67.6	66.9	70.9	75.0	76.8	78.8	74.9	76.4	75.0	80.1	79.0	82.5	79.8		
4-year	83.8	32.0	13.8	14.0	38.8	51.6	58.9	59.0	56.7	57.0	65.6	66.4	65.0	69.3	74.2	76.1	76.8	74.9	74.7	73.4	79.2	79.0	78.1			
5-year	83.8	28.0	10.6	11.8	35.7	48.4	56.7	58.5	55.8	54.2	64.1	60.8	64.7	68.2	72.3	74.0	74.9	74.5	74.7	73.3	77.7	77.6				
6-year	76.9	24.5	8.9	10.9	35.1	45.6	54.6	55.7	53.4	52.8	63.8	59.1	64.4	67.0	70.7	73.1	73.5	73.9	74.1	71.7	76.2					
7-year	76.8	23.5	7.7	10.3	33.4	44.9	49.9	53.1	52.8	52.8	63.0	59.1	60.7	66.8	68.7	72.0	72.5	73.9	72.9	71.7						
8-year	76.8	20.8	6.8	9.9	32.2	44.5	47.2	50.4	52.4	52.4	61.6	57.3	58.5	66.7	67.5	70.2	72.5	71.8	69.6							
9-year	76.8	19.2	6.1	9.5	31.0	42.7	44.8	49.9	52.4	50.8	59.6	57.2	56.8	65.5	65.7	68.3	71.8	71.3								
10-year	76.8	17.2	5.9	9.4	29.9	42.7	43.7	49.9	51.5	48.9	56.9	57.2	56.3	63.0	65.1	66.3	68.4									
11-year	74.7	15.9	5.7	9.2	28.8	42.3	42.4	49.2	50.4	46.7	56.9	57.2	55.6	63.0	65.1	63.0										
12-year	74.7	15.6	5.6	9.2	28.0	41.9	41.2	49.2	50.4	46.1	56.1	57.2	54.7	62.5	64.1											
13-year	74.7	14.7	5.2	9.2	27.5	41.9	40.2	47.9	50.4	45.6	53.7	57.2	54.7	60.4												
14-year	74.7	14.7	5.0	8.9	26.9	40.6	40.2	45.6	49.2	45.6	53.7	57.2	54.1													
15-year	74.7	14.7	4.9	8.7	26.3	40.4	40.2	44.5	48.5	45.6	53.7	57.2														
16-year	74.7	14.7	4.8	8.5	25.8	40.1	40.2	42.9	47.9	45.6	53.2															
17-year	74.7	14.4	4.8	8.4	25.5	38.9	38.8	42.2	45.2	43.3																
18-year	74.7	13.2	4.8	8.2	25.4	38.2	37.7	42.1	45.2																	
19-year	74.7	13.2	4.6	8.0	25.4	38.2	37.7	40.5																		
20-year	74.7	13.2	4.5	7.8	24.9	37.9	37.7																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

Table 10.8
Kaposi SarcomaSEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Survival Time																										
1-year	95.1	63.6	58.7	58.6	60.9	68.8	72.8	73.0	76.9	73.8	79.8	76.9	75.8	81.3	83.0	81.1	82.7	81.2	82.0	83.4	84.1	81.8	87.1	85.8	82.7	83.9
2-year	89.1	41.8	32.1	28.8	45.5	59.8	64.4	64.0	64.8	65.6	73.7	70.2	72.7	72.0	79.4	78.2	80.5	77.2	80.0	77.6	81.0	81.6	84.9	78.3	78.7	
3-year	86.8	33.7	19.0	17.6	41.9	53.8	60.9	59.6	61.2	59.5	68.7	67.4	67.4	69.0	75.9	76.1	78.5	76.0	76.5	74.5	79.2	80.5	83.2	77.4		
4-year	83.7	29.6	13.0	13.3	37.6	51.2	57.3	57.0	56.0	56.7	66.2	66.9	65.2	67.1	75.0	75.6	76.1	76.0	75.1	72.5	78.2	80.5	79.2			
5-year	83.6	25.9	9.7	11.0	35.1	48.1	55.9	56.1	54.9	54.2	64.0	60.7	64.8	65.6	72.9	73.3	73.9	75.4	75.1	72.5	76.9	79.0				
6-year	74.2	22.1	8.0	10.2	34.4	45.4	53.7	54.0	52.0	53.2	64.0	59.0	64.4	63.9	71.1	72.3	72.1	74.7	75.0	71.6	76.6					
7-year	74.1	20.8	6.8	9.6	32.5	44.6	49.5	52.4	51.3	53.2	63.8	59.0	60.3	63.9	68.9	71.1	71.0	74.7	73.5	71.6						
8-year	74.1	18.7	6.0	9.2	31.3	44.2	46.9	50.8	51.2	52.7	62.6	58.1	58.5	63.9	67.6	69.1	71.0	72.4	70.5							
9-year	74.1	17.2	5.4	8.9	30.3	42.3	44.4	50.2	51.2	51.0	60.8	57.8	58.0	63.9	66.1	67.8	70.1	71.9								
10-year	74.1	15.5	5.2	8.7	29.2	42.2	43.1	50.2	50.5	49.6	57.7	57.8	57.5	62.8	65.4	65.6	67.6									
11-year	69.0	14.1	5.0	8.5	28.3	41.9	42.2	49.4	49.2	47.3	57.6	57.8	56.8	62.8	65.4	62.1										
12-year	68.9	13.9	4.9	8.4	27.4	41.4	41.0	49.4	49.2	46.5	56.2	57.8	55.9	62.4	64.4											
13-year	68.9	13.1	4.6	8.4	26.8	41.4	40.0	47.9	48.9	46.0	54.2	57.8	55.9	60.1												
14-year	68.9	13.1	4.4	8.1	26.4	40.4	39.9	45.5	47.1	46.0	54.2	57.8	55.3													
15-year	68.9	13.1	4.4	7.9	25.9	40.2	39.9	44.3	46.1	46.0	54.2	57.1														
16-year	68.9	12.9	4.3	7.8	25.3	39.9	39.9	42.6	45.9	46.0	53.7															
17-year	68.9	12.9	4.3	7.6	25.2	38.7	38.5	41.9	44.1	43.1																
18-year	68.9	12.4	4.3	7.4	25.2	38.0	37.2	41.6	44.1																	
19-year	68.9	12.4	4.1	7.2	25.2	38.0	37.2	40.6																		
20-year	68.9	12.4	4.0	7.0	24.7	37.6	37.2																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

Table 10.9
Kaposi SarcomaSEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Survival Time																										
1-year	92.6	90.0	80.5	80.5	87.2	78.4	73.3	85.1	74.0	78.0	86.3	88.8	64.5	100.0	67.3	89.8	83.7	52.1	86.0	81.6	98.3	64.4	76.5	100.0	89.8	64.3
2-year	90.4	84.0	79.1	63.7	85.9	78.4	73.3	85.1	67.4	76.5	67.5	78.2	64.5	97.2	67.3	89.8	78.0	52.1	71.8	76.9	86.1	64.4	68.4	97.7	81.5	
3-year	90.4	73.4	74.3	57.8	74.5	64.5	73.3	85.0	63.3	67.3	52.1	66.4	55.9	97.2	60.9	82.8	78.0	52.1	71.8	76.9	86.1	59.3	68.4	97.7		
4-year	83.5	69.5	73.6	54.5	74.5	64.5	73.3	85.0	63.3	61.4	52.1	54.7	55.9	97.2	60.9	82.8	78.0	52.1	67.6	76.9	86.1	59.3	63.4			
5-year	81.4	61.0	73.6	53.3	53.7	55.2	66.8	85.0	63.3	52.5	52.1	54.7	55.9	97.2	60.9	82.8	78.0	52.1	59.4	76.9	80.7	54.2				
6-year	81.4	61.0	73.6	49.7	53.7	49.3	66.8	81.4	63.3	43.3	52.1	54.7	55.9	97.2	60.9	82.8	78.0	52.1	59.4	70.2	61.3					
7-year	81.4	61.0	73.6	49.7	53.7	49.3	54.6	54.4	63.3	43.3	50.9	54.7	55.9	97.2	60.9	82.8	78.0	52.1	59.4	70.2						
8-year	81.4	54.1	66.7	49.7	53.7	49.3	47.6	19.5	63.3	43.3	45.9	43.8	55.9	77.2	60.9	82.8	78.0	52.1	56.1							
9-year	81.4	51.0	66.1	48.3	50.7	49.3	47.6	19.5	63.3	43.3	38.0	43.8	21.2	77.2	58.6	75.5	78.0	52.1								
10-year	81.4	45.4	59.8	48.3	48.1	49.3	47.6	19.5	63.0	35.5	38.0	43.8	21.2	51.4	58.6	75.5	74.8									
11-year	81.4	42.7	59.8	48.3	40.3	49.3	41.0	19.5	63.0	35.5	38.0	43.8	21.2	51.4	58.6	75.5										
12-year	81.4	41.9	57.0	48.3	40.3	49.3	41.0	19.5	63.0	35.5	38.0	43.8	21.2	51.4	58.6											
13-year	81.4	41.0	52.4	48.3	40.3	38.4	41.0	19.5	63.0	35.5	0.0	43.8	21.2	51.4												
14-year	81.4	41.0	39.3	48.3	39.0	38.4	41.0	19.5	63.0	35.5	0.0	43.8	21.2													
15-year	81.4	41.0	33.4	48.3	27.5	38.4	41.0	19.5	63.0	35.5	0.0	43.8														
16-year	81.4	41.0	33.4	48.3	27.5	38.4	41.0	19.5	63.0	35.5	0.0															
17-year	81.4	29.3	33.4	48.3	15.6	38.4	41.0	19.5	48.3	35.5																
18-year	80.2	16.6	33.4	48.3	0.0	38.4	41.0	19.5	48.3																	
19-year	80.2	16.6	33.4	48.3	0.0	38.4	41.0	0.0																		
20-year	80.2	16.6	33.4	48.3	0.0	38.4	41.0																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

Table 10.10
Kaposi Sarcoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Both Sexes, 2015-2017 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.00	0.00	0.11	0.00	Asian/ Pacific Islander	0	0.00	0.00	0.00	0.06	0.00
	10	0.00	0.00	0.00	0.11	0.00		10	0.00	0.00	0.00	0.06	0.00
	20	0.00	0.00	0.00	0.11	0.00		20	0.00	0.00	0.00	0.06	0.00
	30	0.00	0.00	0.01	0.12	0.00		30	0.00	0.00	0.01	0.06	0.00
	40	0.00	0.01	0.03	0.12	0.00		40	0.00	0.00	0.01	0.06	0.00
	50	0.01	0.02	0.07	0.12	0.00		50	0.00	0.01	0.03	0.05	0.00
	60	0.02	0.06	0.11	0.12	0.00		60	0.01	0.03	0.04	0.05	0.00
	70	0.05	0.10	-	0.11	0.00		70	0.02	0.04	-	0.05	0.00
80	0.06	-	-	0.08	0.00	80	0.02	-	-	0.03	0.00		
White	0	0.00	0.00	0.00	0.13	0.00	American Indian/ Alaska Native ^a	0	0.00	0.00	0.00	0.08	0.00
	10	0.00	0.00	0.00	0.13	0.00		10	0.00	0.00	0.00	0.08	0.00
	20	0.00	0.00	0.00	0.13	0.00		20	0.00	0.00	0.00	0.08	0.00
	30	0.00	0.00	0.01	0.13	0.00		30	0.00	0.00	0.01	0.08	0.00
	40	0.00	0.01	0.03	0.13	0.00		40	0.00	0.01	0.02	0.08	0.00
	50	0.01	0.03	0.07	0.13	0.00		50	0.01	0.02	0.04	0.09	0.00
	60	0.02	0.07	0.12	0.13	0.00		60	0.02	0.04	0.05	0.09	0.00
	70	0.06	0.11	-	0.12	0.00		70	0.03	0.04	-	0.08	0.00
80	0.07	-	-	0.09	0.00	80	0.01	-	-	0.07	0.00		
Black	0	0.00	0.00	0.00	0.05	0.01	Hispanic ^b	0	0.00	0.00	0.00	0.10	0.00
	10	0.00	0.00	0.00	0.05	0.01		10	0.00	0.00	0.00	0.10	0.00
	20	0.00	0.00	0.00	0.05	0.01		20	0.00	0.00	0.00	0.10	0.00
	30	0.00	0.00	0.01	0.05	0.00		30	0.00	0.00	0.01	0.10	0.00
	40	0.00	0.01	0.01	0.05	0.00		40	0.00	0.01	0.03	0.10	0.00
	50	0.00	0.01	0.03	0.05	0.00		50	0.01	0.03	0.06	0.10	0.00
	60	0.01	0.03	0.05	0.05	0.00		60	0.02	0.05	0.08	0.09	0.00
	70	0.02	0.04	-	0.05	0.00		70	0.03	0.07	-	0.08	0.00
80	0.03	-	-	0.04	0.00	80	0.04	-	-	0.06	0.00		

Devcan 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the PRCA (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 10.11
Kaposi Sarcoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Males, 2015-2017 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.00	0.00	0.18	0.00	Asian/ Pacific Islander	0	0.00	0.00	0.00	0.09	0.00
	10	0.00	0.00	0.00	0.18	0.00		10	0.00	0.00	0.00	0.09	0.00
	20	0.00	0.00	0.00	0.18	0.00		20	0.00	0.00	0.00	0.09	0.00
	30	0.00	0.00	0.01	0.18	0.00		30	0.00	0.00	0.01	0.09	0.00
	40	0.00	0.01	0.04	0.19	0.00		40	0.00	0.01	0.02	0.09	0.00
	50	0.01	0.03	0.10	0.19	0.00		50	0.01	0.02	0.05	0.09	0.00
	60	0.03	0.10	0.18	0.19	0.00		60	0.01	0.05	0.08	0.09	0.00
	70	0.08	0.17	-	0.19	0.00		70	0.04	0.07	-	0.08	0.00
80	0.12	-	-	0.15	0.00	80	0.04	-	-	0.05	0.00		
White	0	0.00	0.00	0.00	0.20	0.00	American Indian/ Alaska Native ^a	0	0.00	0.00	0.00	0.10	0.00
	10	0.00	0.00	0.00	0.20	0.00		10	0.00	0.00	0.00	0.10	0.00
	20	0.00	0.00	0.00	0.20	0.00		20	0.00	0.00	0.00	0.10	0.00
	30	0.00	0.00	0.01	0.20	0.00		30	0.00	0.01	0.01	0.10	0.00
	40	0.00	0.01	0.04	0.20	0.00		40	0.00	0.00	0.03	0.10	0.00
	50	0.01	0.04	0.11	0.21	0.00		50	0.00	0.03	0.06	0.11	0.00
	60	0.03	0.11	0.20	0.21	0.00		60	0.03	0.06	0.07	0.12	0.00
	70	0.09	0.19	-	0.21	0.00		70	0.04	0.05	-	0.10	0.00
80	0.13	-	-	0.16	0.00	80	0.02	-	-	0.09	0.00		
Black	0	0.00	0.00	0.00	0.09	0.01	Hispanic ^b	0	0.00	0.00	0.00	0.16	0.01
	10	0.00	0.00	0.00	0.09	0.01		10	0.00	0.00	0.00	0.16	0.01
	20	0.00	0.00	0.00	0.09	0.01		20	0.00	0.00	0.00	0.16	0.01
	30	0.00	0.00	0.01	0.09	0.01		30	0.00	0.00	0.01	0.16	0.01
	40	0.00	0.01	0.02	0.09	0.01		40	0.00	0.01	0.04	0.16	0.00
	50	0.00	0.02	0.05	0.09	0.00		50	0.01	0.04	0.09	0.17	0.00
	60	0.02	0.05	0.08	0.10	0.00		60	0.03	0.08	0.14	0.16	0.00
	70	0.04	0.08	-	0.10	0.00		70	0.06	0.13	-	0.15	0.00
80	0.07	-	-	0.10	0.00	80	0.09	-	-	0.12	0.00		

Devcan 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the PRCA (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 10.12
Kaposi Sarcoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Females, 2015-2017 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.00	0.00	0.05	0.00	Asian/ Pacific Islander	0	0.00	0.00	0.00	0.03	0.00
	10	0.00	0.00	0.00	0.06	0.00		10	0.00	0.00	0.00	0.03	0.00
	20	0.00	0.00	0.00	0.06	0.00		20	0.00	0.00	0.00	0.03	0.00
	30	0.00	0.00	0.01	0.06	0.00		30	0.00	0.00	0.00	0.03	0.00
	40	0.00	0.01	0.02	0.05	0.00		40	0.00	0.00	0.01	0.03	0.00
	50	0.00	0.01	0.03	0.05	0.00		50	0.00	0.00	0.01	0.03	0.00
	60	0.01	0.03	0.05	0.05	0.00		60	0.00	0.01	0.02	0.03	0.00
	70	0.02	0.04	-	0.04	0.00		70	0.01	0.01	-	0.02	0.00
80	0.02	-	-	0.03	0.00	80	0.01	-	-	0.02	0.00		
White	0	0.00	0.00	0.00	0.06	0.00	American Indian/ Alaska Native ^a	0	0.00	0.00	0.00	0.07	0.00
	10	0.00	0.00	0.00	0.06	0.00		10	0.00	0.00	0.00	0.07	0.00
	20	0.00	0.00	0.00	0.06	0.00		20	0.00	0.00	0.00	0.07	0.00
	30	0.00	0.00	0.01	0.06	0.00		30	0.00	0.00	0.01	0.07	0.00
	40	0.00	0.01	0.02	0.06	0.00		40	0.00	0.01	0.02	0.07	0.00
	50	0.00	0.02	0.04	0.06	0.00		50	0.01	0.02	0.03	0.07	0.00
	60	0.01	0.03	0.05	0.06	0.00		60	0.01	0.02	0.03	0.06	0.00
	70	0.02	0.05	-	0.05	0.00		70	0.02	0.03	-	0.06	0.00
80	0.03	-	-	0.03	0.00	80	0.01	-	-	0.06	0.00		
Black	0	0.00	0.00	0.00	0.02	0.00	Hispanic ^b	0	0.00	0.00	0.00	0.05	0.00
	10	0.00	0.00	0.00	0.02	0.00		10	0.00	0.00	0.00	0.05	0.00
	20	0.00	0.00	0.00	0.02	0.00		20	0.00	0.00	0.00	0.05	0.00
	30	0.00	0.00	0.01	0.02	0.00		30	0.00	0.00	0.01	0.05	0.00
	40	0.00	0.00	0.01	0.02	0.00		40	0.00	0.01	0.02	0.04	0.00
	50	0.00	0.01	0.02	0.02	0.00		50	0.01	0.02	0.03	0.04	0.00
	60	0.01	0.01	0.02	0.02	0.00		60	0.01	0.03	0.04	0.04	0.00
	70	0.01	0.01	-	0.01	0.00		70	0.01	0.02	-	0.03	0.00
80	0.01	-	-	0.01	0.00	80	0.01	-	-	0.01	0.00		

Devcan 6.7.8, April 2020, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the PRCA (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 10.13
Kaposi Sarcoma

SEER Incidence
Age-Adjusted Rates and Trends^a
By Race/Ethnicity and Sex

SEER Incidence	SEER 21 Areas ^b			SEER 21 Areas ^b			SEER 9 Areas ^b		
	Rate 2013-2017			Trend 2008-2017 ^c			Trend 2008-2017 ^d		
	Rate per 100,000 persons			AAPC (%)			AAPC (%)		
Race/Ethnicity	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Races	0.5	0.9	0.1	-3.0*	-3.1*	-3.4*	-2.3*	-2.4*	-3.3*
White	0.4	0.7	0.1	-3.7*	-3.8*	-4.0*	-3.2*	-3.3*	-4.1*
White Hispanic ^e	0.6	1.2	0.1	-4.8*	-4.8*	-17.5	-	-	-
White Non-Hispanic ^e	0.3	0.6	0.1	-3.8*	-3.9*	-4.2*	-	-	-
Black	1.0	2.0	0.2	-2.7*	-2.7*	-3.6*	-1.3*	-1.5*	-
Asian/Pacific Islander	0.2	0.4	-	-1.1	-0.3	-	-	-	-
Amer Ind/Alaska Nat ^f	-	-	-	-	-	-	-	-	-
Hispanic ^e	0.7	1.3	0.2	-4.3*	-4.3*	-3.9*	-	-	-

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 4.8, April 2020, National Cancer Institute.

Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta.

The SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts.

The 2008-2017 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints over diagnosis years 2000-2017.

The 2008-2017 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints over diagnosis years 1975-2017.

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Incidence data for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

The APC is significantly different from zero (p<.05).

Table 10.14
Kaposi Sarcoma

Age-Adjusted SEER Incidence Rates^a
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence Rates^a, 2013-2017</u>									
California	0.54	1.01	0.08	0.51	0.95	0.07	0.88	1.65	-
Greater Bay Area	0.64	1.18	0.12	0.71	1.30	0.13	1.18	2.09	-
San Francisco-Oakland	0.82	1.54	0.12	0.94	1.71	-	1.23	2.30	-
San Jose-Monterey	0.31	0.53	-	0.33	0.58	-	-	-	-
Los Angeles	0.71	1.37	0.09	0.65	1.24	0.08	1.16	2.36	-
Greater California	0.41	0.76	0.07	0.38	0.72	0.05	0.55	0.98	-
Connecticut	0.30	0.56	-	0.28	0.50	-	-	-	-
Detroit	0.42	0.77	-	0.21	0.40	-	0.92	1.74	-
Georgia	0.72	1.42	0.07	0.32	0.62	-	1.53	3.12	-
Atlanta	1.46	2.87	-	0.74	1.44	-	2.53	5.25	-
Rural Georgia	-	-	-	-	-	-	-	-	-
Greater Georgia	0.28	0.56	-	0.15	0.28	-	0.61	1.25	-
Hawaii	0.29	0.56	-	-	-	-	-	-	-
Idaho	-	-	-	-	-	-	-	-	-
Iowa	-	-	-	-	-	-	-	-	-
Kentucky	0.14	0.28	-	0.12	0.23	-	-	-	-
Louisiana	0.48	0.92	-	0.33	0.59	-	0.80	1.68	-
Massachusetts	0.33	0.60	0.08	0.22	0.40	-	1.27	2.34	-
New Jersey	0.40	0.73	0.10	0.33	0.63	-	0.72	1.20	-
New Mexico	0.21	0.36	-	-	-	-	-	-	-
New York	0.67	1.27	0.15	0.53	1.00	0.13	1.02	2.03	0.22
Seattle-Puget Sound	0.36	0.62	-	0.31	0.57	-	-	-	-
Utah	0.17	0.32	-	0.14	0.27	-	-	-	-
SEER 9 Areas ^b	0.52	0.96	0.09	0.36	0.67	0.06	1.51	2.91	0.26
SEER 13 Areas ^b	0.55	1.02	0.09	0.43	0.79	0.07	1.42	2.74	0.23
SEER 18 Areas ^b	0.46	0.86	0.08	0.36	0.68	0.06	1.00	1.91	0.17
SEER 21 Areas ^b	0.48	0.90	0.09	0.38	0.71	0.07	1.02	1.95	0.19

^a Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia

excluding ATL/RG.

The SEER 21 areas comprise the SEER 18 areas plus Idaho, New York and Massachusetts.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 10.15
Kaposi SarcomaEstimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>								
All Races	Both Sexes	8,085	7,440	6,099	5,547	7,325	34,496	+	+
	Males	7,350	6,933	5,862	5,355	7,156	32,656	+	+
	Females	735	507	237	192	169	1,840	+	+
White	Both Sexes	4,870	5,023	4,737	4,064	6,115	24,808	+	+
	Males	4,363	4,628	4,573	3,906	5,985	23,456	+	+
	Females	507	394	164	158	130	1,353	+	+
Black	Both Sexes	2,358	1,882	1,066	1,078	747	7,131	+	+
	Males	2,204	1,817	1,014	1,061	716	6,813	+	+
	Females	153	64	52	17	30	317	+	+
Asian/ Pacific Islander	Both Sexes	159	133	91	61	66	510	+	+
	Males	146	128	88	61	66	489	+	+
	Females	13	5	3	0	0	21	+	+
Hispanic	Both Sexes	1,260	1,162	1,000	873	999	5,294	+	+
	Males	1,132	1,034	969	836	982	4,953	+	+
	Females	128	127	31	38	16	341	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0106	0.0000	0.0000	0.0015	0.0069	0.0154	0.0280	0.0191	0.0137	0.0206	0.0096
	Males	0.0205	0.0001	0.0000	0.0030	0.0133	0.0303	0.0558	0.0389	0.0266	0.0380	0.0189
	Females	0.0011	-	0.0000	-	0.0003	0.0006	0.0015	0.0012	0.0029	0.0097	0.0009
White	Both Sexes	0.0098	0.0000	0.0000	0.0005	0.0038	0.0123	0.0264	0.0185	0.0139	0.0208	0.0083
	Males	0.0187	0.0001	-	0.0011	0.0073	0.0241	0.0522	0.0375	0.0265	0.0385	0.0162
	Females	0.0011	-	0.0001	-	0.0001	0.0003	0.0012	0.0009	0.0031	0.0096	0.0008
Black	Both Sexes	0.0157	0.0001	0.0001	0.0061	0.0242	0.0308	0.0387	0.0232	0.0107	0.0121	0.0162
	Males	0.0312	0.0003	0.0003	0.0122	0.0487	0.0631	0.0798	0.0492	0.0236	0.0234	0.0333
	Females	0.0013	-	-	-	0.0016	0.0022	0.0029	0.0023	0.0016	0.0065	0.0014
Asian/ Pacific Islander	Both Sexes	0.0024	-	-	0.0003	0.0016	0.0047	0.0054	0.0052	0.0040	0.0061	0.0024
	Males	0.0049	-	-	0.0006	0.0033	0.0099	0.0112	0.0110	0.0090	0.0111	0.0051
	Females	0.0002	-	-	-	-	-	0.0005	0.0006	-	0.0029	0.0002
Hispanic	Both Sexes	0.0091	0.0001	-	0.0010	0.0068	0.0163	0.0330	0.0219	0.0199	0.0408	0.0115
	Males	0.0169	0.0001	-	0.0019	0.0129	0.0315	0.0641	0.0436	0.0390	0.0634	0.0218
	Females	0.0012	-	-	-	0.0001	0.0006	0.0022	0.0027	0.0052	0.0267	0.0017

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).


^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Figure 10.1

All Cancer Sites vs Kaposi Sarcoma SEER Incidence Rates, 1975-2017 Males, Ages 20-54






Source: SEER 9 areas.
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines are calculated using the Joinpoint Regression Program Version 4.8, April 2020,
National Cancer Institute.

Figure 10.2

All SEER excluding
San Francisco/Oakland
Males, Ages 20-54
1975-2017

San Francisco/Oakland
Males, Ages 20-54
1975-2017

San Francisco County/City
Males, Ages 20-54
1975-2017



Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

^a Kaposi Sarcoma cases are excluded from Colon & Rectum, Lung & Bronchus, and Non-Hodgkin Lymphoma cases.